Effect of XXXX replacement on @entity3452 , lipids, and apolipoproteins in subjects with @entity1375 .

@entity1 @entity1375 @entity1674 @entity8723 @entity1955 @entity3452 @entity1675 @entity7287 @entity6145 @entity165 @entity597
OBJECTIVE: To study the effect of @entity6145 replacement on total @entity165 , low-density lipoprotein @entity165 , @entity1674 , high-density lipoprotein @entity165 (HDL-C), @entity1675 , and @entity3452 [ @entity3452 ] in subjects with @entity1375 . MATERIAL AND METHODS: In 17 @entity1 with clinical @entity1375 , studies were done before and after @entity6145 replacement therapy. Free @entity1955 and @entity7287 were determined by chemiluminescent assay. Total @entity165 and @entity1674 were measured by enzymatic methods, and HDL-C was measured after dextran @entity597 - @entity8723 precipitation. @entity1675 were assayed by immunonephelometry. For measurement of @entity3452 , we used a sequential sandwich enzyme-linked immunosorbent assay. RESULTS: After @entity1955 treatment, the mean concentration of thyrotropin decreased from 91.4 to 3.7 microIU/mL, and free @entity1955 increased from 0.5 to 1.2 ng/ dL. Total @entity165 , @entity1674 , HDL-C, low-density lipoprotein @entity165 , and @entity1675 decreased after @entity6145 replacement therapy. @entity3452 levels also decreased significantly (P<0.05) after treatment, from a mean of 33.4 to 25.6 mg/dL. CONCLUSION: @entity1375 is associated with an increase in total @entity165 , @entity1674 , HDL-C, @entity1675 , and @entity3452 . A reduction in lipid and lipoprotein levels after @entity6145 replacement in our study cohort resulted in a less atherogenic profile.
